{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:01:50Z","timestamp":1790758910957,"version":"4.1.0"},"reference-count":21,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T00:00:00Z","timestamp":1393891200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T00:00:00Z","timestamp":1393891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2014,4]]},"abstract":"\n Objective<\/jats:title>\n \n Cysteine-rich, angiogenic inducer, 61 (\n CYR61<\/jats:italic>\n ) is a key gene in the transforming growth factor-\u03b2 signalling pathway, which is involved in the development of many tumour types. This study aimed to clarify the status and clinical significance of\n CYR61<\/jats:italic>\n expression in patients with ovarian epithelial carcinoma.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Tissue from patients with ovarian epithelial carcinoma or benign ovarian tumours were investigated retrospectively for\n CYR61<\/jats:italic>\n expression at mRNA and protein levels, using reverse transcription\u2013polymerase chain reaction and immunohistochemistry, respectively. Correlations between immunohistochemical scores and several clinicopathological parameters were investigated.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In 50 patients with ovarian epithelial carcinoma and 50 patients with benign ovarian tumours,\n CYR61<\/jats:italic>\n expression on mRNA and protein levels was significantly higher in ovarian epithelial carcinoma tissue than in benign ovarian tissue.\n CYR61<\/jats:italic>\n expression was associated with regional lymph node metastases and progression of clinical disease stage. There was no difference in\n CYR61<\/jats:italic>\n expression between patients aged <50 years and \u226550 years.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n CYR61<\/jats:italic>\n expression was significantly upregulated in ovarian carcinoma tissue compared with benign ovarian tumour tissue samples. Protein CYR61 levels were associated with lymph node metastases and Union for International Cancer Control stage. Protein CYR61 may be useful in targeted diagnosis and therapy, for patients with ovarian epithelial carcinoma.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/0300060513505268","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T21:39:54Z","timestamp":1393969194000},"page":"300-306","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Cysteine-rich, angiogenic inducer, 61 expression in patients with ovarian epithelial carcinoma"],"prefix":"10.1177","volume":"42","author":[{"given":"Yang","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, the Second Hospital, Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianmin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, the Second Hospital, Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, the Second Hospital, Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manhua","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, the Second Hospital, Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,3,4]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"627","article-title":"Current approach to epithelial ovarian cancer based on the concept of cancer stem cells","volume":"17","author":"Djordjevic B","year":"2012","unstructured":"Djordjevic B, Stojanovic S, Conic I, et al. Current approach to epithelial ovarian cancer based on the concept of cancer stem cells. J BUON 2012; 17: 627\u2013636.","journal-title":"J BUON"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12010-012-9829-y"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1385\/1592590713"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0300060513487652"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C300430200"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.34.24113"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00229"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81460-9"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.02.019"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010149200"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.11.023"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.2853"},{"key":"e_1_3_3_14_2","first-page":"4375","article-title":"Stromal thrombospondin-1 expression is correlated with progression of esophageal squamous cell carcinomas","volume":"19","author":"Oshiba G","year":"1999","unstructured":"Oshiba G, Kijima H, Himeno S, et al. Stromal thrombospondin-1 expression is correlated with progression of esophageal squamous cell carcinomas. Anticancer Res 1999; 19: 4375\u20134378.","journal-title":"Anticancer Res"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/13547500600896791"},{"key":"e_1_3_3_16_2","volume-title":"TNM Classification of Malignant Tumors","author":"Sobin LH","year":"1997","unstructured":"Sobin LH, Wittekind C. International Union against Cancer. TNM Classification of Malignant Tumors, 5th ed. New York: John Wiley, 1997.","edition":"5"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(92)90060-G"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000121000"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207628"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.11.6355"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009755200"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.6.8186"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060513505268","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0300060513505268","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060513505268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:52:17Z","timestamp":1777459937000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0300060513505268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1177\/0300060513505268"],"URL":"https:\/\/doi.org\/10.1177\/0300060513505268","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,4]]}}}